Goldman Sachs analyst Salveen Richter upgraded Ionis Pharmaceuticals (IONS) to Neutral from Sell with a price target of $65, up from $45. The firm says Ionis is transitioning to a commercial growth story and has optimized its antisense oligonucleotide technology. The positive Phase 3 Tryngolza data in severe hypertriglyceridemia showed a significant impact on the key acute pancreatitis endpoint, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $80 from $78 at Barclays
- Ionis Pharmaceuticals price target raised to $86 from $71 at Morgan Stanley
- Ionis Pharmaceuticals price target raised to $83 from $81 at BofA
- Ionis Pharmaceuticals price target raised to $92 from $90 at Guggenheim
- Buy Rating for Ionis Pharmaceuticals: Promising Phase 3 Results for Zilganersen in Alexander Disease